New melanoma drug gets Medsafe registration for lung cancerSUPPLIED Keytruda is an immunotherapy drug used to treat advanced melanoma and, more recently, lung cancer. A new drug which was recently funded for melanoma treatment is now registered for lung cancer treatment in New Zealand. Keytruda (pembrolizumab) this week received its second Medsafe registration for lung cancer, pharmaceutical company Merck Sharp and Dohme (MSD) announced. MSD New Zealand Director Paul Smith said the drug had the potential to transform the way lung cancer is treated. Lung cancer is the country's biggest cancer killer, with more than 1600 Kiwis dying of it each year.

Source: Stuff April 21, 2017 03:40 UTC